Table 1 Flow-MRD response assessment after treatment of multiple myeloma

(A)

Patients registered/included into the study

Patients included into the study (Inclusion period: 01-03-2012 - 31-03-2014)

136

79

Patients with only diagnostic BM sample received (until 31-10-2018)

83

Patients with BM samples for Flow-MRD analysis received (until 31-08-2018)

53

29

(B)

1st flow RA (Flow-MRD analysis FU1)

Patients with BM samples received for 1st Flow-RA

53

Excluded patients not reaching RS of CR at 1st response assessment

31

13

Excluded patients (OFF-protocol)

1

1

Included patients with RS of CR/SCR at 1st response assessment

21

14

Included with adequate BM sample

15

Excluded with inadequate BM sample

6

(C)

Longitudinal flow-MRD analysis (FU1-FUX)

Patients with BM samples received for longitudinal analysis

53

Best reached RS during the patients course: <VGPR

2

1

Best reached RS during the patients course: VGPR

11

10

Best reached RS during the patients course: CR

12

5

Best reached RS during the patients course: sCR

28

13

Excluded patients (Off-protocol)

2

Excluded patients not reaching CR over the entire patients course

13

Excluded with inadequate BM samples (until progression)

4

Included patients with reached RS CR/SCR over the patients course

34

Included with ≥ 3 Flow-MRD samples analysed (incl. FU1)

20

7

Excluded with ≤ 2 Flow-MRD samples analysed (incl. FU1)

14

7